{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T18:22:52Z","timestamp":1787595772097,"version":"build-2736575974"},"reference-count":35,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001238","name":"Merck Company Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001238","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>\n                    Carbapenem resistance in\n                    <jats:italic>Pseudomonas aeruginosa<\/jats:italic>\n                    and Enterobacterales is a growing threat, with intrinsic and acquired resistance mechanisms resulting in the need for new therapeutic options. In Peru, data on resistance patterns and the effectiveness of new antibiotic combinations are limited A descriptive, cross-sectional, retrospective study was conducted on\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    and Enterobacterales clinical isolates collected from 2019 to 2024 at a reference laboratory in Lima, Peru, originating from various public and private healthcare centers. Bacterial identification was performed using VITEK MS MALDI-TOF, and antimicrobial susceptibility testing via VITEK 2 and\/or Kirby-Bauer disk diffusion. Carbapenemase production was detected using colorimetric, immunochromatographic, and molecular methods, including the FilmArray\u00ae BCID panel for bloodstream infections. Microbiological and epidemiological variables were analyzed with Poisson regression models. A total of 173,308 isolates were analyzed, with\n                    <jats:italic>E. coli<\/jats:italic>\n                    (74%) and\n                    <jats:italic>K. pneumoniae<\/jats:italic>\n                    (10.6%) being most prevalent. Most samples (92%) were urinary. Meropenem resistance in\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    reached 33% overall and 60% in respiratory specimens.\n                    <jats:italic>K. pneumoniae<\/jats:italic>\n                    showed 3.4% carbapenem resistance. Among carbapenem-resistant isolates, 43.7% were carbapenemase producers. Carbapenemase production was highest in carbapenem-resistant\n                    <jats:italic>K. pneumoniae<\/jats:italic>\n                    (93.1%),\n                    <jats:italic>E. coli<\/jats:italic>\n                    (87.3%), and\n                    <jats:italic>P. mirabilis<\/jats:italic>\n                    (77.3%), but only 32.7% in\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    . Among carbapenemase-producing Enterobacterales, metallo-\u03b2-lactamases predominated, with bla-NDM detected in 69.6% of\n                    <jats:italic>K. pneumoniae<\/jats:italic>\n                    and bla-OXA-48-like in 100% of\n                    <jats:italic>E. coli<\/jats:italic>\n                    . Ceftazidime\/avibactam (CZA) and ceftolozane\/tazobactam (C\/T) were highly active (&gt;89%) against non-carbapenemase-producing\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    , but &lt;1% effective against producers. Resistance was more common in northern, eastern, and southern Lima.\n                    <jats:italic>P. aeruginosa<\/jats:italic>\n                    exhibited high carbapenem resistance, largely driven by non-carbapenemase mechanisms, supporting the role of C\/T for treatment of non-carbapenemase-producing carbapenem-resistant\n                    <jats:italic>P. aeruginosa.<\/jats:italic>\n                    Among Enterobacterales, carbapenemase production was frequent in carbapenem-resistant isolates, with metallo-\u03b2-lactamases predominating. The limited activity of CZA against MBL producers underscores the urgent need for novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations to address MBL-producing Enterobacterales.\n                  <\/jats:p>","DOI":"10.1371\/journal.pone.0356004","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:26:36Z","timestamp":1787592396000},"page":"e0356004","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Carbapenem resistance and susceptibility to Ceftazidima\/avibactam and Ceftolozane\/tazobactam in Pseudomonas aeruginosa and Enterobacterales in a reference laboratory in Lima, Peru: A cross-sectional study"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4566-2027","authenticated-orcid":true,"given":"Juan Carlos","family":"G\u00f3mez de la Torre Pretell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Hueda-Zavaleta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2677-7179","authenticated-orcid":true,"given":"Luis","family":"Alvarado R\u00edos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Valenzuela-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto Martin","family":"La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thales","family":"Polis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"pone.0356004.ref001","unstructured":"World Health Organization. Antimicrobial resistance. World Health Organization. 2023. Accessed 2025 July 16. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/antimicrobial-resistance"},{"key":"pone.0356004.ref002","volume-title":"Tackling drug-resistant infections globally: final report and recommendations","author":"J O\u2019Neill","year":"2016"},{"issue":"10325","key":"pone.0356004.ref003","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"CJ Murray","year":"2022","journal-title":"The Lancet"},{"issue":"10258","key":"pone.0356004.ref004","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/S0140-6736(20)30925-9","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"C Abbafati","year":"2020","journal-title":"Lancet"},{"key":"pone.0356004.ref005","unstructured":"La OMS publica la lista de las bacterias para las que se necesitan urgentemente nuevos antibi\u00f3ticos. Accessed 2024 March 16. https:\/\/www.who.int\/es\/news\/item\/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed"},{"issue":"3","key":"pone.0356004.ref006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"E Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"pone.0356004.ref007","article-title":"The WHO bacterial priority pathogens list 2024: a prioritisation study to guide research, development, and public health strategies against antimicrobial resistance","author":"AS Sati","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"pone.0356004.ref008","doi-asserted-by":"crossref","first-page":"175","DOI":"10.4266\/acc.2021.00409","article-title":"Identification and infection control of carbapenem-resistant Enterobacterales in intensive care units","volume":"36","author":"J Yi","year":"2021","journal-title":"Acute Crit Care"},{"issue":"12","key":"pone.0356004.ref009","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1086\/648451","article-title":"Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase\u2013producing K. pneumoniae","volume":"30","author":"LB Gasink","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"12","key":"pone.0356004.ref010","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054971","article-title":"Impact of carbapenem resistance on mortality in patients infected with Enterobacteriaceae: a systematic review and meta-analysis","volume":"11","author":"R Zhou","year":"2021","journal-title":"BMJ Open"},{"issue":"12","key":"pone.0356004.ref011","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01105-21","article-title":"Detection and characterization of targeted carbapenem-resistant health care-associated threats: findings from the antibiotic resistance laboratory network, 2017 to 2019","volume":"65","author":"S Sabour","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"pone.0356004.ref012","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1473-3099(19)30755-8","article-title":"Molecular and clinical epidemiology of carbapenem-resistant Enterobacteriaceae in the United States: a prospective cohort study","volume":"20","author":"D van Duin","year":"2020","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"pone.0356004.ref013","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"D van Duin","year":"2017","journal-title":"Virulence"},{"issue":"5","key":"pone.0356004.ref014","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.4269\/ajtmh.22-0556","article-title":"Prevalence of antimicrobial resistance in gram-negative bacteria bloodstream infections in peru and associated outcomes: VIRAPERU study","volume":"109","author":"F Krapp","year":"2023","journal-title":"Am J Trop Med Hyg"},{"key":"pone.0356004.ref015","doi-asserted-by":"crossref","unstructured":"Tamma PD, Aitken SL, Bonomo RA, Mathers AJ, van Duin D, Clancy CJ. Infectious Diseases Society of America Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections 2024 Update. Infectious Diseases Society of America (IDSA). 2024. Accessed 2025 June 4. https:\/\/www.idsociety.org\/practice-guideline\/amr-guidance\/","DOI":"10.1093\/cid\/ciad428"},{"key":"pone.0356004.ref016","unstructured":"World Health Organization. Global antimicrobial resistance and use surveillance system (GLASS) dashboard. Accessed 2025 June 4. https:\/\/worldhealthorg.shinyapps.io\/glass-dashboard\/"},{"key":"pone.0356004.ref017","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.jgar.2022.06.018","article-title":"In vitro activity of aztreonam\/avibactam against isolates of Enterobacterales collected globally from ATLAS in 2019","volume":"30","author":"GM Rossolini","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"7","key":"pone.0356004.ref018","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1093\/cid\/ciw856","article-title":"Epidemiology of carbapenem-resistant klebsiella pneumoniae in a network of long-term acute care hospitals","volume":"64","author":"JH Han","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"12","key":"pone.0356004.ref019","first-page":"1189","article-title":"International Nosocomial Infection Control Consortium (INICC) report of health care\u2013associated infections: data summary of 45 countries for 2015 to 2020, adult and pediatric units, device-associated module","volume":"51","author":"VD Rosenthal","year":"2023","journal-title":"Am J Infect Control"},{"key":"pone.0356004.ref020","first-page":"105103","article-title":"Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy","volume":"105","author":"K Zhou","year":"2022","journal-title":"Infect Genet Evol"},{"key":"pone.0356004.ref021","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jgar.2022.08.018","article-title":"Mechanisms of carbapenemase-mediated resistance among high-risk Pseudomonas aeruginosa lineages in Peru","volume":"31","author":"IA Tickler","year":"2022","journal-title":"J Glob Antimicrob Resist"},{"issue":"1","key":"pone.0356004.ref022","first-page":"3","article-title":"First report of KPC-35-producing Klebsiella pneumoniae ST258 isolated in Peru.","author":"A Gonzales-Rodriguez","year":"2025","journal-title":"Rev Argent Microbiol"},{"issue":"2","key":"pone.0356004.ref023","article-title":"First report of OXA-181-producing Enterobacterales isolates in Latin America","volume":"11","author":"D Cuicapuza","year":"2023","journal-title":"Microbiol Spectr"},{"issue":"6","key":"pone.0356004.ref024","doi-asserted-by":"crossref","first-page":"104589","DOI":"10.1016\/j.bjid.2025.104589","article-title":"Guideline for antimicrobial treatment of multidrug-resistant Gram-negative infections: practice recommendations of the Brazilian Society of Infectious Diseases","volume":"29","author":"AP Zavascki","year":"2025","journal-title":"Braz J Infect Dis"},{"issue":"8","key":"pone.0356004.ref025","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00405-23","article-title":"Ceftolozane-tazobactam versus ceftazidime-avibactam for the treatment of infections caused by multidrug-resistant pseudomonas aeruginosa: a multicenter cohort study","volume":"67","author":"TA Almangour","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"pone.0356004.ref026","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00907-24","article-title":"Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam","volume":"68","author":"DA Hareza","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"pone.0356004.ref027","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/S1473-3099(24)00648-0","article-title":"Effectiveness of ceftazidime-avibactam versus ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections in the USA (CACTUS): a multicentre, retrospective, observational study","volume":"25","author":"RK Shields","year":"2025","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"pone.0356004.ref028","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/cid\/ciw243","article-title":"Ceftazidime\/Avibactam and Ceftolozane\/Tazobactam: second-generation \u03b2-lactam\/\u03b2-lactamase inhibitor combinations","volume":"63","author":"D van Duin","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pone.0356004.ref029","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1093\/cid\/ciz816","article-title":"Ceftolozane\/tazobactam vs polymyxin- or aminoglycoside-based regimens for the treatment of drug-resistant Pseudomonas aeruginosa","volume":"71","author":"A Pogue","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"6","key":"pone.0356004.ref030","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.cmi.2024.11.006","article-title":"Aztreonam and avibactam combination therapy for metallo-\u03b2-lactamase-producing gram-negative bacteria: a narrative review","volume":"31","author":"G Sangiorgio","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"1","key":"pone.0356004.ref031","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.diagmicrobio.2018.11.008","article-title":"Nephrotoxicity prevalence in patients treated with polymyxins: a systematic review with meta-analysis of observational studies","volume":"94","author":"AF Oliota","year":"2019","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"pone.0356004.ref032","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1093\/cid\/ciaa586","article-title":"Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-\u03b2-lactamase\u2013producing Enterobacterales","volume":"72","author":"M Falcone","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"pone.0356004.ref033","article-title":"Aztreonam-avibactam susceptibility testing program for metallo-beta-lactamase-producing Enterobacterales in the antibiotic resistance laboratory network, March 2019 to December 2020","volume":"65","author":"A Bhatnagar","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"pone.0356004.ref034","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.3390\/antibiotics10081012","article-title":"The revival of aztreonam in combination with avibactam against metallo-\u03b2-lactamase-producing gram-negatives: a systematic review of in vitro studies and clinical cases","volume":"10","author":"C Mauri","year":"2021","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"pone.0356004.ref035","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1093\/cid\/ciad725","article-title":"Clinical features and outcomes of infections caused by metallo-\u03b2-lactamase\u2013producing Enterobacterales: a 3-year prospective study from an endemic area","volume":"78","author":"M Falcone","year":"2024","journal-title":"Clin Infect Dis"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356004","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T17:26:43Z","timestamp":1787592403000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0356004"}},"subtitle":[],"editor":[{"given":"Farah","family":"Al-Marzooq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":35,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0356004","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]}}}